Polymer-drug conjugates: Towards a novel approach for the treatment of endrocine-related cancer

Endocrine-Related Cancer

Volumn 12, Issue SUPPL. 1, 2005, Pages

  Duncan, R ^a   Vicent, M J ^a,b   Greco, F ^a   Nicholson, R I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMINOGLUTETHIMIDE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; BEVACIZUMAB; CAMPTOTHECIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; GALACTOSAMINE; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; MELPHALAN; METHOTREXATE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; NAVELBINE; PACLITAXEL; PEGINTERFERON ALPHA2B; POLYGLUTAMIC ACID; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB; UNINDEXED DRUG; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER; ZINOSTATIN STIMALMER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CARDIOTOXICITY; CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; CYSTITIS; DRUG CONJUGATION; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; HEPATITIS C; HORMONAL THERAPY; HUMAN; IN VITRO STUDY; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHATIC LEUKEMIA; METASTASIS; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; MULTIPLE SCLEROSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; POLYMERS;

EID: 25844524902     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01045     Document Type: Conference Paper

References (60)

1. Allen TM 2002 Ligand-targeted therapeutics in anticancer therapy. Nature Reviews. Drug Discovery 2 750-763.
2. Atalay G, Cardoso F, Awada A & Piccart MJ 2003 Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Annals of Oncology 14 1346-1363.
3. Atkins JH & Gershell LJ 2002 Selective anticancer drugs. Nature Reviews. Cancer 1 645-646.
4. Auzenne E, Donato NJ, Leroux E, Price RE, Farquhar D & Klostergaard J 2002 Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic campartmental models of human ovarian carcinoma. Clinical Cancer Research 8 573-581.
5. Brekke O & Sandlie I 2003 Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nature Reviews. Drug Discovery 2 52-62.
6. Brodie AMH & Njar VCO 2000 Aromatase inhibitors and their application in breast cancer treatment. Steroids 65 171-179.
7. Chabner BA & Roberts TG 2005 Timeline - chemotherapy and the war on cancer. Nature Reviews. Cancer 5 65-72.
8. Coleman MP 1999 Opinion: why the variation in breast cancer survival in Europe? Breast Cancer Research 1 22-26.
9. Cummings F 2002 Evolving uses of hormonal agents for breast cancer therapy. Clinical Therapeutics 24 C3-25.
10. Daub H, Specht K & Ullrich A 2004 Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Reviews. Drug Discovery 3 1001-1010.
11. Duncan R 1992 Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs 3 175-210.
12. Duncan R 2003a The dawning era of polymer therapeutics. Nature Reviews. Drug Discovery. 2 347-360.
13. Duncan R 2003b Polymer-drug conjugates. In Handbook of Anticancer Drug Development, pp 239-260. Eds D Budman, H Calvert & E Rowinsky. Philadelphia, USA: Lippincott, Williams & Wilkins.
14. Duncan R 2005a N-(2-Hydroxypropyl)methacrylamide copolymer conjugates. In Polymeric Drug Delivery Systems, pp 1-92. Ed. GS Kwon. New York: Marcel Dekker.
15. Duncan R 2005b Targeting and intracellular delivery of drugs. In Encyclopedia of Molecular Cell Biology and Molecular Medicine, in press. Ed. RA Meyers. Weinheim, Germany: Wiley-VCH Verlag.
16. Duncan R & Kopecek J 1984 Soluble synthetic polymers as potential drug carriers. Advances in Polymer Science 57 51-101.
17. Duncan R, Gac-Breton S, Keane R, Musila R, Sat YN, Satchi R & Searle F 2001 Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to the clinic. Journal of Controlled Release 74 135-146.
18. Ferrara N, Hillan KJ, Gerber H-P & Novotny W 2004 Case history: discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Reviews. Drug Discovery 3 391-400.
19. Ferrari M 2005 Cancer nanotechnology: opportunities and challenges. Nature Reviews. Cancer 5 161-171.
20. Gianasi E, Wasil M, Evagorou EG, Keddle A, Wilson G & Duncan R 1999 HPMA copolymer platinates as novel antitumor agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. European Journal of Cancer 35 994-1002.
21. Gianasi E, Buckley RG, Latigo J, Wasil M & Duncan R 2002 HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. Journal of Drug Targeting 10 549-556.
22. Goss PE & Strasser K 2002 Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs 62 957-966.
23. Greenwald RB, Choe YH, McGuire J & Conover CD 2003 Effective drug delivery by PEGylated drug conjugates. Advanced Drug Delivery Reviews 55 217-250.
24. Haran PM 2004 Epidermal growth factor receptor inhibition strategies in oncology. Endocrine-Related Cancer 11 689-708.
25. Harries M & Smith I 2002 The development and clinical use of trastuzumab (Herceptin). Endocrine-Related Cancer 9 75-85.
26. Harris JM & Chess RB 2003 Effect of pegylation on pharmaceuticals. Nature Reviews. Drug Discovery 2 214-221.
27. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton I, Locker GY & Tobias JS 2005 Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 60-62.
28. Hreczuk-Hirst D, Chicco D, German L & Duncan R 2001 Dextrins as potential carriers for drug targeting: tailored rates of dextrin degradation by introduction of pendant groups. International Journal of Pharmaceutics 230 57-66.
29. Igney FK & Krammer PH 2002 Death and anti-death: tumour resistance to apoptosis. Nature Reviews Cancer 2 277-288.
30. Jordan MA & Wilson L 2004 Microtubules as a target for anticancer drugs. Nature Reviews. Cancer 4 253-265.
31. Jordan VC 2003 Tamoxifen: a most unlikely pioneering medicine. Nature Reviews. Drug Discovery 2 206-213.
32. Li C, Yu D, Newman R, Cabral F, Stephens LC, Hunter N, Milas L & Wallace S 1998 Complete regression well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Research 58 2404-2409.
33. Lønning PE 2004 Aromatase inhibitors in breast cancer. Endocrine-Related Cancer 11 179-189.
34. Malik N, Evagorou EG & Duncan R 1999 Dendrimer-platinate: a novel approach to cancer chemotherapy. Anti-Cancer Drugs 10 767-776.
35. Matsumura Y & Maeda H 1986 A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Research 6 6387-6392.
36. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JHM, Schot M, Mandjes IAM, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ & Beijnen JH 2001 Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs 12 315-323.
37. Nakanishi T, Fukushima S, Okamoto K, Suzuki M., Matsumura Y, Yokoyama M, Okano T, Sakurai Y & Kataoka K 2001 Development of the polymer micelle carrier system for doxorubicin, Journal of Controlled Release 74 295-302.
38. Nishiyama N, Nori A, Malugin A, Kasuya Y, Kopeckova P & Kopecek J 2003 Free and N-(2-hydroxypropyl)-methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells. Cancer Research 63 7876-7882.
39. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T & Maeda H 1998 Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Japanese Journal of Cancer Research 89 307-314.
40. Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, de Boer RF, Pluim D, Beijnen JH, Schellens JH & Droz J-P 2004 A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clinical Cancer Research 10 3386-3395.
41. Rihova B, Strohalm J, Prausova J, Kubackova K, Jelinkova M, Rozprimova L, Sirova M, Plocova D, Etrych T, Subr V, Mrkvan T, Kovar M & Ulbrich K 2003 Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. Journal of Controlled Release 91 1-16.
42. Ringsdorf H 1975 Structure and properties of pharmacologically active polymers. Journal of Polymer Science Polymer Symposium 51 135-153.
43. Sarapa N, Britto MR, Speed W, Jannuzzo MG, Breda M, James C, Porro MG, Rocchetti M & Nygren P 2003 Targeted delivery and preferential uptake in solid cancer of MAG-CPT, a polymer bound prodrug of camptothecin - a trial in patients undergoing surgery for colorectal carcinoma. Cancer Chemotherapy Pharmacology 52 424-430.
44. Satchi R, Connors TA & Duncan R 2001 PDEPT: polymer directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination. British Journal of Cancer 85 1070-1076.
45. Satchi-Fainaro R, Hailu H, Davies JW, Summerford C & Duncan R 2003 PDEPT: polymer directed enzyme prodrug therapy. II. HPMA copolymer-β- lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjugate Chemistry 14 797-804.
46. Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G & Folkman J 2004 Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nature Medicine 10 225-261.
47. Schoemaker NE, van Kesteren C, Rosing H, Jansen, Swart M, Lieverst J, Fraier D, Breda M, Pellizzoni C, Spinelli R, Grazia PM, Beijnen JH, Schellens JH & Bokkel Huinink WW 2002 A phase I clinical and pharmacokinetic study of MAG-CPT, a water soluble polymer conjugate of camptothecin. British Journal of Cancer 87 608-614.
48. Searle F, Gac-Breton S, Keane R, Dimitrijevic S, Brocchini S & Duncan R 2001 N-(2-Hydroxypropyl)methacrylamide copolymer-6-(3-aminopropyl)- ellipticine conjugates, synthesis, characterisation and preliminary in vitro and in vivo studies. Bioconjugate Chemistry 12 711-718.
49. Seymour LW, Miyamoto Y, Brereton M, Subr V, Strohalm J & Duncan R 1995 Influence of molecular size on passive tumour-accumulation of soluble macromolecular drug carriers. European Journal of Cancer 5 766-770.
50. Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Payner R, Doran J, Young AM, Burtles S & Kerr DJ 2002 Hepatic drug targeting: phase I evaluation of polymer bound doxorubicin. Journal of Clinical Oncology 20 1668-1676.
51. Singer CF, Hudelist G, Lamm W, Mueller R, Czerwenka K & Kubista E 2004 Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocrine-Related Cancer 11 861-869.
52. Sledge GW Jr & Miller KD 2003 Exploiting the hallmarks of cancer: the future conquest of breast cancer. European Journal of Cancer 39 1668-1675.
53. Tomlinson R, Klee M, Garrett S, Heller J, Duncan R & Brocchini S 2002 Pendent chain functionalised polyacetals that display pH-dependent degradation: a platform for the development of novel polymer therapeutics. Macromolecules 35 473-480.
54. Tomlinson R, Heller J, Brocchini S & Duncan R 2003 Polyacetal-doxorubicin conjugates designed for pH-dependent degradation. Bioconjugate Chemistry 14 1098-1106.
55. Torchilin VP 2005 Recent advances with liposomes as pharmaceutical carriers. Nature Reviews. Drug Discovery 4 145-160.
56. Varticovski L, Lu Z-R, Mitchell K, de Aos I & Kopecek J 2001 Water-soluble HPMA copolymer wortmannin conjugate retains phosphoinositide 3-kinase inhibitory activity in vitro and in vivo. Journal of Controlled Release 74 275-281.
57. Vasey P, Kaye SB, Morrison R, Twelves C, Wilson P, Duncan R, Thomson AH, Murray LS, Hilditch TE, Murray T, Burtles S, Fraier D, Frigerio E & Cassidy J 1999 Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clinical Cancer Research 5 83-94.
58. Vicent MJ, Manzanaro S, de la Fuente JA, Pérez C & Duncan R 2004a HPMA copolymer-1,5-diazaanthraquinone conjugates as promising anticancer therapeutics. Journal of Drug Targeting 12 503-515.
59. Vicent MJ, Tomlinson R, Brocchini S & Duncan R 2004b Polyacetal-diethylstilboestrol: a polymeric drug designed for pH-triggered activation. Journal of Drug Targeting 12 491-501.
60. Vicent MJ, Greco F, Nicholson RI & Duncan R 2005 Polymer-drug conjugates as a novel combination therapy for the treatment of hormone-dependent cancers. Angewante Chemie (in press).